癌症生物标记市场规模、份额、成长分析，按分析技术、按癌症类型、按产品、按应用、按地区 - 行业预测，2024-2031 年

2022年，癌症生物标记的全球市场规模为238亿美元，从2023年的264.7亿美元成长到2031年的618.8亿美元，预计在预测期内（2024-2031年）将成长。为11.8%。

全球癌症生物标记市场的预期成长与乳癌、摄护腺癌和肺癌等各种癌症盛行率的上升密切相关。这些癌症发生率的增加是未来几年推动市场扩张的关键因素。此外，生物标的疗法在癌症治疗中的重要性日益增加，推动了对有效生物标记的需求。技术进步透过提高癌症生物标记的准确性和可靠性，最终提高诊断准确性和治疗监测，在这一成长趋势中发挥关键作用。这些技术创新将有助于改善患者预后并进一步加速市场成长。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 价格分析
• 专利分析
• 价值链分析
• 供应链分析
• 贸易分析
• 技术分析
• 客户和购买标准分析
• 案例研究分析

癌症生物标记市场：依分析技术分类

• 市场概况
• 体学技术
  • 蛋白质体学
  • 免疫检测
  • 质谱分析
  • 二维凝胶电泳
  • 蛋白质微阵列
  • 其他蛋白质体技术
  • 基因组学
  • 次世代定序
  • 聚合酵素链锁反应
  • 原位杂交
  • 其他体学技术
• 成像技术
  • 超音波影像诊断
  • 电脑断层扫描
  • 磁振造影
  • 正子断层扫描
  • 乳房X光照相术

癌症生物标记市场：按癌症类型分类

• 非何杰金氏淋巴瘤
• 乳癌
• 肺癌
• 大肠直肠癌
• 摄护腺癌
• 恶性黑色素瘤
• 白血病
• 甲状腺癌
• 膀胱癌
• 非何杰金氏淋巴瘤
• 肾癌
• 其他癌症

癌症生物标记市场：副产品

• 市场概况
• 装置
  • 影像设备
  • 病理学设备
  • 切片检查仪器
• 消耗品
  • 抗体
  • 试剂套件和试剂
  • 探测
• 生物资讯软体

癌症生物标记市场：按应用分类

• 市场概况
• 诊断
• 研究与开发
• 预言
• 风险评估
• 其他用途

癌症生物标记市场：依最终用户分类

• 市场概况
• 诊断实验室
• 与生物製药公司交叉
• 研究/学术机构
• 其他最终用户

癌症生物标记市场：按地区分類的规模

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• F. Hoffmann-La Roche Ltd.（Switzerland）
• Thermo Fisher Scientific Inc.（US）
• Qiagen（Netherlands）
• Bio-Rad Laboratories, Inc.（US）
• Illumina, Inc.（US）
• Agilent Technologies, Inc.（US）
• Abbott Laboratories（US）
• bioMerieux（France）
• Merck KGaA（Germany）
• Becton, Dickinson and Company（US）
• Myriad Genetics, Inc.（US）
• Sysmex Corporation（Japan）
• Hologic, Inc.（US）
• Quest Diagnostics（US）
• Centogene NV（Germany）
• BioGenex（US）
• Siemens Healthineers（Germany）
• Exact Sciences（US）
• R&D Systems, Inc.（US, part of Bio-Techne）
• Biovision Inc.（US）
• Olink（Sweden）
• Meso Scale Diagnostics, LLC（US）
• Invivoscribe, Inc.（US）
• INOVIQ Ltd.（Australia）

Global Cancer Biomarkers Market size was valued at USD 23.8 billion in 2022 and is poised to grow from USD 26.47 billion in 2023 to USD 61.88 billion by 2031, growing at a CAGR of 11.8% during the forecast period (2024-2031).

The anticipated growth of the global cancer biomarkers market is closely tied to the rising prevalence of various cancer types, including breast, prostate, and lung cancers. The increasing incidence of these cancers is a key factor driving the market's expansion in the coming years. Moreover, the growing importance of biological and targeted therapies in cancer treatment is boosting the demand for effective biomarkers. Technological advancements play a critical role in this upward trend by improving the accuracy and reliability of cancer biomarkers, ultimately enhancing diagnostic precision and treatment monitoring. These innovations contribute to better patient outcomes, further accelerating the market's growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Biomarkers Market Segmental Analysis

Global Cancer Biomarkers Market is segmented by Profiling Technology, Cancer Type, Product, Application, End User and region. Based on Profiling Technology, the market is segmented into Omics Technologies, Imaging Technologies. Based on Cancer Type, the market is segmented into Non-Hodgkin's Lymphoma, Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkin's Lymphoma, Kidney Cancer, and Other Cancers. Based on Product, the market is segmented into Instruments, Bioinformatics Software. Based on Application, the market is segmented into Diagnostics, Research & Development, Prognostics, Risk Assessment, and Other Applications. Based on End User, the market is segmented into Diagnostic Laboratories, Biopharmaceutical Companies and Cros, Research and Academic Institutes, Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Cancer Biomarkers Market

Many pharmaceutical companies are actively investing in cutting-edge research and development aimed at creating innovative biomarkers specifically designed for cancer diagnosis and treatment. Several of these biomarkers are approaching the final stages of development and are expected to make a substantial impact once introduced to the market. These upcoming biomarkers have the potential to transform cancer care by offering improved accuracy and effectiveness in both diagnosis and treatment. Their introduction could lead to more personalized approaches, significantly enhancing patient outcomes and setting new standards in the management of cancer.

Restraints in the Global Cancer Biomarkers Market

The increasing global incidence of cancer and the growing need for diagnostic tests highlight a major challenge in the cancer biomarker market: the lack of extensive reimbursement policies for biomarker tests in both emerging and developed countries. This gap in coverage limits the widespread adoption of these essential diagnostic tools, thereby restraining the global demand for biomarkers. Moreover, the high costs associated with cancer diagnosis and treatment, which are particularly burdensome in emerging economies, pose a significant obstacle. These financial constraints further impede the accessibility and use of advanced biomarkers, affecting their market growth and adoption.

Market Trends of the Global Cancer Biomarkers Market

The cancer biomarkers market is set for substantial growth over the next decade, driven by several key factors. A major catalyst is the increasing awareness among patients and healthcare professionals about the crucial role early detection plays in managing cancer. This growing understanding promotes a proactive approach to diagnosis, leading to earlier interventions that can significantly enhance treatment effectiveness. This shift towards early detection is expected to stimulate demand for cancer biomarkers, as timely identification of malignancies can lead to better outcomes and more effective treatments. As awareness continues to rise, the market for these diagnostic tools is likely to expand, reflecting the critical need for advancements in cancer care.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Pricing Analysis
• Patent Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Trade Analysis
• Technology Analysis
• Customer & Buying Criteria Analysis
• Case Study Analysis

Cancer Biomarkers Market by Profiling Technology

• Market Overview
• Omics Technologies
  • Proteomics
  • Immunoassays
  • Mass Spectrometry
  • 2D Gel Electrophoresis
  • Protein Microarrays
  • Other Proteomic Technologies
  • Genomics
  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • In Situ Hybridization
  • Other Omics Technologies
• Imaging Technologies
  • Ultrasound Imaging
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Positron Emission Tomography
  • Mammography

Cancer Biomarkers Market by Cancer Type

• Non-Hodgkin'S Lymphoma
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Leukemia
• Thyroid Cancer
• Bladder Cancer
• Non-Hodgkin's Lymphoma
• Kidney Cancer
• Other Cancers

Cancer Biomarkers Market by Product

• Market Overview
• Instruments
  • Imaging Instruments
  • Pathology-Based Instruments
  • Biopsy Instruments
• Consumables
  • Antibodies
  • Kits & Reagents
  • Probes
• Bioinformatics Software

Cancer Biomarkers Market by Application

• Market Overview
• Diagnostics
• Research & Development
• Prognostics
• Risk Assessment
• Other Applications

Cancer Biomarkers Market by End User

• Market Overview
• Diagnostic Laboratories
• Biopharmaceutical Companies And Cros
• Research And Academic Institutes
• Other End Users

Cancer Biomarkers Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Centogene N.V. (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioGenex (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• R&D Systems, Inc. (US, part of Bio-Techne)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biovision Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olink (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Meso Scale Diagnostics, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invivoscribe, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• INOVIQ Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments